Exenatide is a GLP-1 receptor agonist, a peptide whose amino acid sequence partly overlaps human GLP-1. It was first approved in the United States as Byetta in 2005.1,2 It is FDA-approved, with diet and exercise, to improve blood-sugar control in adults with type 2 diabetes. Drugs@FDA also lists Bydureon, Bydureon BCise and a generic exenatide application.1,3,4,5 A large outcomes trial of a longer-acting exenatide product in 14,752 adults found that it did not increase major cardiovascular events but did not show that it reduced them.7 On November 13, 2026, FDA published its determination that Byetta was not withdrawn from sale for reasons of safety or effectiveness.6
Exenatide at a glance
What it is
A GLP-1 receptor agonist. The label states that its amino acid sequence partly overlaps that of human GLP-1.1
FDA status
FDA-approved. Drugs@FDA lists Byetta (first approved April 28, 2005), Bydureon (January 27, 2012), Bydureon BCise (October 20, 2017) and a generic application (November 19, 2024). The cited generic label has no boxed warning.1,2,3,4,5
Human evidence
Randomized, placebo-controlled blood-sugar trials described in the label and a large cardiovascular outcomes trial of a longer-acting exenatide product.1,7
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
What is exenatide?
Exenatide is a peptide that acts like GLP-1, a hormone released by the gut. The label states that its amino acid sequence partly overlaps that of human GLP-1.1
Drugs@FDA lists it as the active ingredient of Byetta, Bydureon and Bydureon BCise, and of a generic exenatide application approved on November 19, 2024. The label cited on this page is a generic exenatide label.1,2,3,4,5
How does exenatide work?
The label states that exenatide binds to and activates the GLP-1 receptor, increasing insulin release from the pancreas when blood sugar is high.1
The label also states that it suppresses inappropriately high glucagon release and slows stomach emptying, lowering blood sugar both when fasting and after meals.1
What do human studies show?
The label describes randomized, placebo-controlled trials in adults with type 2 diabetes, including a 24-week trial of 232 adults and three 30-week trials that together randomized 1,446 adults. Exenatide lowered HbA1c, a measure of long-term blood sugar, more than placebo.1
In EXSCEL, 14,752 adults with type 2 diabetes, 73.1% of whom had previous cardiovascular disease, were randomized to a longer-acting exenatide product or placebo. The main cardiovascular outcome occurred in 11.4% and 12.2% of the groups, a result that met the trial’s safety criterion but not its criterion for showing benefit.7
What the evidence base contains
Large randomized human trial EXSCEL: a randomized, placebo-controlled cardiovascular outcomes trial of a longer-acting exenatide product in 14,752 adults with type 2 diabetes, followed for a median of 3.2 years.7
Large randomized human trial Three 30-week randomized, double-blind, placebo-controlled trials described in the label, which together randomized 1,446 adults whose type 2 diabetes was not controlled by metformin, a sulfonylurea or both.1
Controlled human trial A 24-week randomized, double-blind, placebo-controlled trial in 232 adults with type 2 diabetes in which exenatide was the only diabetes medicine.1
Yes. Drugs@FDA lists Byetta, application NDA021773, with an original approval date of April 28, 2005; Bydureon (NDA022200) on January 27, 2012; Bydureon BCise (NDA209210) on October 20, 2017; and a generic exenatide application (ANDA206697) on November 19, 2024.2,3,4,5
The generic exenatide label cited here (DailyMed SPL version 17, published June 30, 2026) states that it is indicated as an adjunct to diet and exercise to improve blood-sugar control in adults with type 2 diabetes.1
That label has no boxed warning. It states that exenatide is contraindicated in people with a prior severe allergic reaction to it or a history of drug-induced immune thrombocytopenia from exenatide products, a loss of blood platelets that can cause serious or fatal bleeding.1
Its other warnings cover acute pancreatitis, low blood sugar when combined with insulin or insulin secretagogues, kidney injury from fluid loss, severe gastrointestinal reactions, antibodies to exenatide, allergic reactions, gallbladder disease and aspiration during anesthesia or deep sedation.1
On November 13, 2026, FDA published a Federal Register notice listing Byetta among drug products that are no longer marketed and determining that it was not withdrawn from sale for reasons of safety or effectiveness.6
Timeline
FDA approves Byetta, the first exenatide product, according to Drugs@FDA.2
Results of the EXSCEL cardiovascular outcomes trial are published.7
FDA approves Bydureon BCise, according to Drugs@FDA.4
FDA approves a generic exenatide application, according to Drugs@FDA.5
DailyMed publishes the generic exenatide label version cited on this page.1
FDA publishes its determination that Byetta was not withdrawn from sale for reasons of safety or effectiveness.6
What is still unknown?
Whether exenatide reduces cardiovascular events: EXSCEL did not meet its criterion for showing benefit.7
How the labels for other exenatide products differ: this page cites one generic label, and the EXSCEL trial studied a longer-acting product.1,7
Its effects in people without type 2 diabetes: the label covers adults with type 2 diabetes only.1
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Exenatide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Exenatide are the records PeptideScanner has selected and published, not every registration or paper about Exenatide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
FDA-approved as Byetta, Bydureon and generic exenatide. Randomized trials described in the label show lower HbA1c than placebo. A large outcomes trial of a longer-acting exenatide product did not show a reduction in cardiovascular events. In November 2026 FDA determined that Byetta was not withdrawn from sale for safety or effectiveness reasons.↗↗↗↗↗↗↗
Review source snapshots checked August 19, 2026 · Integrity checked August 19, 2026.
A bounded review of two randomized placebo-controlled trials in type 2 diabetes: one short monotherapy trial and one large cardiovascular-outcomes trial.↗↗
What the reviewed sources report
The short monotherapy trial reported improved glycated hemoglobin and weight measures. The larger outcomes trial established cardiovascular noninferiority but did not meet its superiority criterion for major cardiovascular events.↗↗
What remains unresolved?
Which populations, if any, have durable patient-important benefits beyond glycemic control, and how do outcomes change after treatment discontinuation?↗↗
This injection label covers glycemic control alongside diet and exercise in adults with type 2 diabetes. Its formulation-specific account does not substitute for extended-release exenatide labeling. Label: 1 ↗
Which safety limits matter?
Contraindications include severe hypersensitivity and prior exenatide-induced immune-mediated thrombocytopenia. Warnings address pancreatitis, hypoglycemia with insulin or insulin secretagogues, kidney injury from volume depletion, severe gastrointestinal reactions, antibodies, potentially fatal bleeding from immune-mediated thrombocytopenia, gallbladder disease and aspiration during anesthesia or deep sedation. Label: 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 3a938f95f72fa59782922c490dc415fef7aa62df9872a1da096e4bff95b65abb. Extracted XML SHA-256: 18efb84e3d03a7719a6efd35e086f73cfc27232395a36db93da5fe7334894977.
A bounded review of two randomized placebo-controlled trials in type 2 diabetes: one short monotherapy trial and one large cardiovascular-outcomes trial.21
Bottom line from this bounded source set
The short monotherapy trial reported improved glycated hemoglobin and weight measures. The larger outcomes trial established cardiovascular noninferiority but did not meet its superiority criterion for major cardiovascular events.21
Reviewed study record
Monotherapy trial
Design
A double-blind randomized placebo-controlled trial assessed glycemic measures, weight, and tolerability over 24 weeks.2
Population
The trial included 232 adults with type 2 diabetes that was inadequately controlled with diet and exercise and who had not used antidiabetic drugs.2
Outcomes reported
Mean glycated-hemoglobin reductions were 0.7 and 0.9 percentage points in the two exenatide groups and 0.2 points with placebo. Mean weight reductions were 2.8 and 3.1 kilograms versus 1.4 kilograms.2
Limitations
The trial was small and 24 weeks long, and its surrogate and weight outcomes do not establish longer-term clinical benefit or rare harms.2
Reviewed study record
EXSCEL cardiovascular-outcomes trial
Design
A sponsor-funded randomized placebo-controlled cardiovascular-outcomes trial followed participants for a median of 3.2 years alongside usual care.1
Population
The trial randomized 14,752 adults with type 2 diabetes; 73.1% had previous cardiovascular disease.1
Outcomes reported
The primary cardiovascular outcome occurred in 11.4% of the exenatide group and 12.2% of the placebo group. The comparison met noninferiority for safety but not superiority for efficacy.1
Limitations
The pragmatic trial included participants with and without prior cardiovascular disease, and its borderline superiority result should not be reframed as proof of cardiovascular benefit.1
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa1612917. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/j.clinthera.2008.08.006. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
The original trials tested add-on diabetes treatment
EMA’s original Byetta assessment evaluated exenatide added to existing glucose-lowering therapy in type 2 diabetes. HbA1c was the principal endpoint; weight change was a separate outcome. This is not the later extended-release or cardiovascular-outcomes evidence. EMA PDF pp. 25, 27 ↗
More findings, study links and document coverage
The insulin comparisons had an important limitation
Two active-comparator trials met the prespecified HbA1c noninferiority margin. EMA noted their open-label design and the possibility that insulin treatment had not been fully optimized, limiting claims that one treatment was better overall. EMA PDF pp. 25 ↗
Extension results require caution
EMA warned that more than 80% of extension participants withdrew or discontinued for administrative reasons after week 52. Favorable results among those remaining cannot alone establish durable benefit for everyone originally enrolled. EMA PDF pp. 25 ↗
Safety depends on accompanying treatment and follow-up
The review identifies nausea and vomiting as common problems and hypoglycemia particularly with sulfonylureas. Mean exposure was under a year, with limited experience in older people and impaired kidney function. EMA PDF pp. 26 ↗
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
The undated initial scientific discussion names the product. Application identity comes from the separately pinned EMA medicine record, and the date is the documents-feed first-publication date, not an adoption date.
Verified: Byetta · EMEA/H/C/000698 · EMA first-publication date 2006-12-15. Product identity checked on PDF pp. 1.
The undated PDF does not print the application number. The application is reconciled separately against EMA medicine record EMEA/H/C/000698 ↗, retrieved 2026-09-15. Its first-publication date is not an assessment-adoption date.
Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.
Retrieved 2026-09-19. Read PDF pages: 1, 25, 26, 27 of 27. SHA-256: 406dfeecb0b57c3036d836ebf625e6aad6182143b50820c441500b79c3a2d1df.
Feed-listed application (not a verified association): EMEA/H/C/000698.
Remaining work
Review the separate Bydureon extended-release assessment and EXSCEL cardiovascular program.
Reconcile later safety variations and full-text trial reports with their original study populations.
European medicine records · 2 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: exenatide. EMA record ↗
Marketing authorisation: 2006-11-20. EMA metadata last updated 2024-11-06. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
2851 retrieved · 2 included · 0 excluded · 2849 awaiting a decision · 0 full-text appraisals
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
PMID18803987 has an ErratumIn relation without a notice PMID in the retrieved record; notice identity and effects remain unresolved.
Showing 25 of 2851 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 28910237 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01144338.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 18803987 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: exenatide-PMID18803987-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed links an erratum: Clin Ther. 2008 Oct;30(10):1937. Impact on the selected study summary remains unresolved.
PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42725235 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42721371 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42714656 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42709517 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42695140 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42692277 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42687799 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42682267 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42675372 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42669385 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42666495 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42654342 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42644866 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42609010 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42603384 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 30000037 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42594084 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42585299 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42584027 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42570075 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42539351 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42536830 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
5 retrieved · 5 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA ANDA206697 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: EXENATIDE SYNTHETIC.
FDA NDA021773 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: EXENATIDE SYNTHETIC.
FDA NDA022200 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: EXENATIDE SYNTHETIC.
FDA NDA021919 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: EXENATIDE SYNTHETIC.
FDA NDA209210 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: EXENATIDE SYNTHETIC.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/002020 — include: EMA feed product Bydureon; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/000698 — include: EMA feed product Byetta; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
44 retrieved · 29 included · 0 excluded · 15 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 44 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 6123 — include: Document linked by EMA product number; content unappraised. Byetta : EPAR - Summary for the public
EMA 11126 — include: Document linked by EMA product number; content unappraised. Bydureon : EPAR - All Authorised presentations
EMA 12068 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-2020-PSUV-0024 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 12420 — include: Document linked by EMA product number; content unappraised. Byetta : EPAR - All Authorised presentations
EMA 14627 — include: Document linked by EMA product number; content unappraised. Byetta : EPAR - Procedural steps taken before authorisation
EMA 19721 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-2020-PSUV-0014 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 22590 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-002020-II-0045 : EPAR - Assessment report - Variation
EMA 23204 — include: Document linked by EMA product number; content unappraised. Bydureon : EPAR - Summary for the public
EMA 25728 — include: Document linked by EMA product number; content unappraised. Byetta-H-C-698-II-0021 : EPAR - Assessment Report - Variation
EMA 26196 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-2020-II-0041 : EPAR - Assessment Report - Variation
EMA 29015 — include: Document linked by EMA product number; content unappraised. Byetta-H-C-698-PSUV-0045 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 29706 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-PSUSA-00009147-201503 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 30099 — include: Document linked by EMA product number; content unappraised. Byetta-H-C-698-II-0029 : EPAR - Assessment Report - Variation
EMA 30953 — include: Document linked by EMA product number; content unappraised. Bydureon : EPAR - Public assessment report
EMA 31353 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-2020-PSU-0014 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 31694 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-2020-PSUV-0018 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 36540 — include: Document linked by EMA product number; content unappraised. Byetta : EPAR - Scientific Discussion
EMA 37951 — include: Document linked by EMA product number; content unappraised. Byetta-PSUSA-00009147-201503 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 42298 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-2020-X-0048-G : EPAR - Assessment Report - Extension
EMA 50315 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-PSUSA-00009147-202003 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 50316 — include: Document linked by EMA product number; content unappraised. Bydureon-H-C-2020-P46-028 : EPAR - Assessment report
EMA 50318 — include: Document linked by EMA product number; content unappraised. Byetta-PSUSA-00009147-202003 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
EMA 55742 — include: Document linked by EMA product number; content unappraised. Bydureon : EPAR - Risk management plan summary
EMA 60626 — include: Document linked by EMA product number; content unappraised. Byetta-H-C-698-P46-048 : EPAR - Assessment report
EMA 58772 — include: Document linked by EMA product number; content unappraised. Byetta : EPAR - Risk-management-plan summary
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EU/3/23/2793 — include: EMA orphan feed identifies exenatide; designation status: Positive. Orphan designation is not marketing authorization.
EMA EU/3/16/1629 — include: EMA orphan feed identifies exenatide; designation status: Positive. Orphan designation is not marketing authorization.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
408 retrieved · 0 included · 0 excluded · 408 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 408 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT00569907 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00775684 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01208649 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04268862 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02170324 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01602913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02325960 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00679042 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02586831 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01934816 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01677104 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01302327 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00097500 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02847403 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04615910 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02162550 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02584582 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04159766 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00744224 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00845182 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05034783 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02541734 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01511393 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02793154 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02288273 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Exenatide?
FDA-approved as Byetta, Bydureon and generic exenatide. Randomized trials described in the label show lower HbA1c than placebo. A large outcomes trial of a longer-acting exenatide product did not show a reduction in cardiovascular events. In November 2026 FDA determined that Byetta was not withdrawn from sale for safety or effectiveness reasons.↗↗↗↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
A phase value is unavailable here for 47 selected records; this is not counted as “no phase.”
A status value is unavailable here for 46 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
25 of 49 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 22Randomized Controlled Trial 5Research Support, Non-U.S. Gov't 5Multicenter Study 4Case Reports 2Clinical Trial 2Comparative Study 2Letter 2Clinical Trial, Phase II 1Comment 1Editorial 1Patient Education Handout 1Research Support, N.I.H., Extramural 1Research Support, U.S. Gov't, Non-P.H.S. 1Review 1
Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
5
FDA Federal Register documents
11
DailyMed SPL versions
5
Canonical profile
Published
Profile structured data
Published
Linked dated records
120
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 120 dated records
PubMed revised the bibliographic metadata of PMID 42709517, with a metadata revision date of 2026-10-30. This version reports that observation; the earlier retained observation remains available as version 1.
We added a plain-language reader guide with cited answers, re-checked the generic exenatide label, added the Drugs@FDA approval records and the EXSCEL outcomes trial, and added FDA’s November 13, 2026 determination that Byetta was not withdrawn from sale for safety or effectiveness reasons.
The Federal Register published notice 2026-23141, attributed to FDA and its parent HHS department, on 2026-11-13. Its official title is “Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
Selected records span April 28, 2005 to November 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
The Federal Register published notice 2026-23141, attributed to FDA and its parent HHS department, on 2026-11-13. Its official title is “Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.↗
PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
The Federal Register published notice 2026-16998, attributed to FDA and its parent HHS department, on 2026-08-20. Its official title is “Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 30974038 at 2026-08-10T10:49:06.835Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2019-04-12. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT05663515 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was exenatide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41364402 at 2026-08-10T18:13:38.016Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2025-12-09. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42171611 at 2026-08-10T18:13:50.652Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42290292 at 2026-08-10T18:13:52.268Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41865922 at 2026-08-10T18:13:44.869Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-03-22. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41597428 at 2026-07-30T16:11:44.888Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-28. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
DailyMed lists Structured Product Labeling version 17 for the reviewed Exenatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 39919773 at 2026-07-30T16:14:10.828Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2025-02-07. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.↗